Life Sciences Discipline, Burnet Institute, Melbourne, Victoria, Australia.
Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
J Infect Dis. 2021 Aug 16;224(4):667-672. doi: 10.1093/infdis/jiaa775.
Statins may help prevent cardiovascular disease (CVD) in people with human immunodeficiency virus (PWH) with chronic inflammation owing to their pleotropic lipid-lowering and anti-inflammatory properties.
The impact of 48 weeks of rosuvastatin therapy on inflammation and immune activation in a double-blind, placebo-controlled trial in PWH at moderate cardiovascular disease risk was assessed.
Rosuvastatin did not alter plasma levels of interleukin 6, soluble tumor necrosis factor receptor type 2, CXCL10, soluble CD14, or soluble vascular cellular adhesion molecule 1 (P ≥ .1 for all). Proportions of CD16+ monocyte subsets were increased in PWH receiving rosuvastatin.
The potential benefits of statin use in PWH with normal lipid levels requires further clinical outcome research.
他汀类药物具有多效性的降脂和抗炎特性，可能有助于预防因慢性炎症而导致心血管疾病（CVD）的人类免疫缺陷病毒（HIV）感染者（PWH）发生 CVD。
在具有中度 CVD 风险的 PWH 中进行了一项为期 48 周的、双盲、安慰剂对照试验，评估了瑞舒伐他汀治疗对炎症和免疫激活的影响。
瑞舒伐他汀并未改变血浆中白细胞介素 6、可溶性肿瘤坏死因子受体 2、CXCL10、可溶性 CD14 或可溶性血管细胞黏附分子 1 的水平（所有 P 值均≥.1）。接受瑞舒伐他汀治疗的 PWH 中 CD16+单核细胞亚群的比例增加。
对于血脂水平正常的 PWH，他汀类药物的潜在益处需要进一步的临床结局研究。
